to and for you, thank earnings call for new our his Good us want as first Todd everyone, morning I today. Branding Thank Mark. joining CFO. welcome you
in to significant again. business. integrate, was agreed to turn slide to ahead. and forward Please as with to grow look and join he XXXX excited his Amneal our year guidance, you experience, continued for the and work are We leadership we a six. it’s of we Amneal great to Todd, years progress diversify
tentative we We approvals, products U.S. new industry led the year last numerous demonstrated throughout XX by are approvals, of growth the both XX approvals our and and focus on achievements strength, operational our Amneal as and excellence, generics from launched. Notably, sequential through foundation ANDA in building launches, year. a including XX
Phase X dosed combination company the strong growth submitting we XX completed of our our of group R&D in IPXXXX. nine integration. our major for our completed May, very was XXXX, the Rytary, months delivered we segment had This from ANDAs scheduled study and our revenue In end what tasks the And of and Specialty Our included integration the active December, script first we facility Unithroid. reshaping we initially ahead the Amneal. and Hayward of pre planning. Impax in through approximately manufacturing By in of patients shutting down
included Lannett faster through deployed year, a $XXX Makena amount as on what are with more pace version rate strategically $XX Levothyroxine, with million laboratories the the partnership and had originally of partnerships. and planned. Jerome we at Regent capital we result, These Throughout the achieve in agreements As Stevens and in mAbxience. approximately our captured cost Generic and and than biosimilar American to acquisition we synergies accelerated track of several for of savings, the million, a as with well we Avastin of Gemini for than
capture to now a several our perspective, through business synergies XX accelerated from and an benefited we our from factors, investments launches new Turning year basis, slide a to business development, financial seven, at on base performance. product full rate, strategic ability including
As a diluted and flat, at adjusted $XXX earnings $X.XX. combined essentially revenues result, were combined adjusted XX% share grew per EBITDA XXXX to million by although in combined came
Fourth earnings a and for quarter, on a Turning basis, grew ago. and X% XX% compared a delivered of quarter X% combined year we eight, the streak solid grew EBITDA basis. a financial share three to consecutive of sequential to year-over-year. diluted continuing quarters results, adjusted And sequential on net fourth and XX% slide XX% operational growth. sequential sequential revenue per grew Adjusted a basis, on
financial the covers to I’d highlights segments. Before Todd of details results, our from like our review
year had to our with a advanced our our portfolio slide return opportunities. generic strategy to we a a value, focus and higher on higher look Turning diversify nine to execution at great of pipeline take segment,
the generics lead the shown with XX As slide, U.S. on approvals. Amneal ANDA industry
the through accelerating XX launched net move product rate million we also We with XXX year. of new products new in introductions revenue as the contribution representing
or launching is high are This launches to selecting demonstrated at right proud our means injectable, we than both products we were our launch which This from of and we are not especially are product group. and by are fact product is hundred operationally approved, peer also our diversifying We note them. the the executing products topical families. liquid portfolio relative XX% generic Of products, more very two our commercially. getting but further new of excelling that only generic of ratio,
were growth. sustainable generic forms. made pipeline Turning of now to committed effort and to Slide is drive XXXX about XX, this as it generics XX value, Amneal not it’s comes great heard our just about you diversified have say non-oral solid as the building Amneal when to before, business, a to in dosage quantity, by with progress for submitted ANDA it’s us XX% We
products submitted current XXX at FDA. pending includes Our the pipeline
launched is products. of the approvals nine ANDA XXXX momentum approvals, first through Our carrying tentative we’ve two already two and months two with
the have XX upto this opportunity We year. launch products to
Slide to the update XX, of Turning generic for development R&D pipeline.
focused products. have that XXXX. durable, our As potential shown pipeline XX, solid products and Specialty higher On be a in complex the are to this have thirds on and here, in value. non-oral delivered revenue Slide more more company’s and growth dosage we in products R&D year-over-year sequential demonstration investing approximately is sustainable of the our the segment, Again, two of emphasis on which recap
had wins we we December week in on our franchise, for had grew an XXXX continued Within We we improving all-time access per focus total and the managed in growth, Rytary off net and several patients. scripts by year-over-year XXXX. of in important high care XX% sales as important
Our job team executing of new importance and of with has and Rytary on the the connect done a better patients. established our proposition fantastic prescribers value both
sales XXXX, another nasal ZOMIG specialty spray, to net headwinds. care managed In important now grew franchise. year-over-year overcoming Turning XX%
affordability maximize patient are actively We brand to taking and to steps penetration. access improve
Turning XXXX over Emverm, franchises double prior XX, both grew and potential by new net XX% Slide two the prescriptions. now year to believe Unithroid with in discuss the to growth and have that sales Unithroid’s growth. digit for in specialty total we
product there to as XXXX. implementing Looking potential force includes continued half deliver the forward, executing well in existing growth believe as our this of we Emverm we declined promotional committed expansion and the year. growth sales strategy to This over sales X% is second strategies brand. are the for on for
for replace an marks cards access increased X Phase on as affordability. study point our direct-to-physician increase IPXXXX, action start for new the already also patient XXXX to promotion. We have includes This XXXX highlighted copay of implemented a of and of to plan e-voucher the launch slide and awareness, sale XX.
We are first game is the a top in with line patients continue date in expect for changer data off enrolling the of filing potential time patients dosing, product BID This opportunity Parkinson’s disease. suffering to which half has XXXX a a and to XXXX. and from reduce
I over the We’re turn the to about Todd will opportunity. this walk With to excited through that, financials. call
